Skip to main content
Top
Published in: Medical Oncology 2/2013

01-06-2013 | Original Paper

Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia

Authors: Ana Rosa da Silveira Costa, Anupama Vasudevan, Ana Krepischi, Carla Rosenberg, Maria de Lourdes L. F. Chauffaille

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

Acute myeloid leukemia (AML) is a group of clonal diseases, resulting from two classes of mutation. Investigation for additional abnormalities associated with a well-recognized subtype, core-binding factor AML (CBF-AML) can provide further understanding and discrimination to this special group of leukemia. In order to better define genetic alterations in CBF-AML and identify possible cooperating lesions, a single-nucleotide polymorphism-array (SNP-array) analysis was performed, combined to KIT mutation screening, in a set of cases. Validation of SNP-array results was done by array comparative genomic hybridization and FISH. Fifteen cases were analyzed. Three cases had microscopic lesions better delineated by arrays. One case had +22 not identified by arrays. Submicroscopic abnormalities were mostly non-recurrent between samples. Of relevance, four regions were more frequently affected: 4q28, 9p11, 16q22.1, and 16q23. One case had an uncovered unbalanced inv(16) due to submicroscopic deletion of 5´MYH11 and 3´CBFB. Telomeric and large copy number neutral loss of heterozygosity (CNN-LOH) regions (>25 Mb), likely representing uniparental disomy, were detected in four out of fifteen cases. Only three cases had mutation on KIT gene, enhancing the role of abnormalities by SNP-array as presumptive cooperating alterations. Molecular karyotyping can add valuable information to metaphase karyotype analysis, emerging as an important tool to uncover and characterize microscopic, submicroscopic genomic alterations, and CNN-LOH events in the search for cooperating lesions.
Literature
2.
go back to reference Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179–98.PubMedCrossRef Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002;3:179–98.PubMedCrossRef
3.
go back to reference Downing JR. The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev. 2003;13(1):48–54.PubMedCrossRef Downing JR. The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev. 2003;13(1):48–54.PubMedCrossRef
4.
go back to reference Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood. 2007;110(3):799–805.PubMedCrossRef Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood. 2007;110(3):799–805.PubMedCrossRef
5.
go back to reference Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741–50.PubMedCrossRef Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741–50.PubMedCrossRef
6.
go back to reference Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haemato. 2006;135(2):165–73.CrossRef Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haemato. 2006;135(2):165–73.CrossRef
8.
go back to reference Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112(4):965–74.PubMedCrossRef Maciejewski JP, Mufti GJ. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008;112(4):965–74.PubMedCrossRef
9.
go back to reference Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
10.
go back to reference O’Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731–9.PubMedCrossRef O’Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731–9.PubMedCrossRef
11.
go back to reference Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372–9.PubMedCrossRef Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372–9.PubMedCrossRef
12.
go back to reference Costa AR, Belangero SI, Melaragno MI, Chauffaille ML. Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML. Med Oncol. 2012;29(3):2083–7.PubMedCrossRef Costa AR, Belangero SI, Melaragno MI, Chauffaille ML. Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML. Med Oncol. 2012;29(3):2083–7.PubMedCrossRef
13.
go back to reference Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematol Am Soc Hematol Educ Program. 2009;2009:385–95.CrossRef Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematol Am Soc Hematol Educ Program. 2009;2009:385–95.CrossRef
14.
go back to reference Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65(2):375–8.PubMed Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65(2):375–8.PubMed
15.
go back to reference Tiu R, Gondek L, O′Keefe C, Huh J, Sekeres M, Elson P, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid eulemia. J Clin Oncol. 2009;27(31):5219–26.PubMedCrossRef Tiu R, Gondek L, O′Keefe C, Huh J, Sekeres M, Elson P, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid eulemia. J Clin Oncol. 2009;27(31):5219–26.PubMedCrossRef
16.
go back to reference Kelly J, Foot NJ, Conneally E, Enright H, Humphreys M, Saunders K, et al. 3′CBFbeta deletion associated with inv(16) in acute myeloid leukemia. Cancer Genet Cytogenet. 2005;162(2):122–6.PubMedCrossRef Kelly J, Foot NJ, Conneally E, Enright H, Humphreys M, Saunders K, et al. 3′CBFbeta deletion associated with inv(16) in acute myeloid leukemia. Cancer Genet Cytogenet. 2005;162(2):122–6.PubMedCrossRef
17.
go back to reference Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, et al. Wwox inactivation enhances mammary tumorigenesis. Oncogene. 2011;30(36):3900–6.PubMedCrossRef Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, et al. Wwox inactivation enhances mammary tumorigenesis. Oncogene. 2011;30(36):3900–6.PubMedCrossRef
18.
go back to reference Ekizoglu S, Muslumanoglu M, Dalay N, Buyru N. Genetic alterations of the WWOX gene in breast cancer. Med Oncol. 2012;29:1529–35.PubMedCrossRef Ekizoglu S, Muslumanoglu M, Dalay N, Buyru N. Genetic alterations of the WWOX gene in breast cancer. Med Oncol. 2012;29:1529–35.PubMedCrossRef
19.
go back to reference O’Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett. 2006;232(1):37–47.PubMedCrossRef O’Keefe LV, Richards RI. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett. 2006;232(1):37–47.PubMedCrossRef
20.
go back to reference Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood. 2012;119(10):e67–75.PubMedCrossRef Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. Blood. 2012;119(10):e67–75.PubMedCrossRef
21.
go back to reference Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464(7289):704–12.PubMedCrossRef Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464(7289):704–12.PubMedCrossRef
Metadata
Title
Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia
Authors
Ana Rosa da Silveira Costa
Anupama Vasudevan
Ana Krepischi
Carla Rosenberg
Maria de Lourdes L. F. Chauffaille
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0579-7

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue